Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL126667 | 0.94 | PARP10 (0.45) | KMT2AMAPTTDP1L3MBTL1MEN1 | |
| SCHEMBL8956431 | 0.89 | PARP10 (0.42) | KMT2AMAPTTDP1L3MBTL1MEN1 | |
| SCHEMBL9871665 | 0.82 | KMT2A (0.56) | KMT2AMAPTL3MBTL1MEN1SMN1; SMN2 | |
| SCHEMBL13222378 | 0.81 | HSD17B10 (0.50) | KMT2AMAPTTDP1MEN1SMN1; SMN2 | |
| SCHEMBL13578697 | 0.80 | MAPT (0.39) | KMT2AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL13578473 | 0.78 | EGFR (0.41) | KMT2AMAPTMEN1SMN1; SMN2NPC1 | |
| SCHEMBL11688488 | 0.78 | PARP10 (0.56) | KMT2AMAPTTDP1L3MBTL1MEN1 | |
| SCHEMBL6938009 | 0.78 | PARP10 (0.69) | KMT2AMAPTTDP1L3MBTL1MEN1 | |
| SCHEMBL9874346 | 0.78 | KMT2A (0.50) | KMT2AMAPTL3MBTL1MEN1SMN1; SMN2 | |
| SCHEMBL9874348 | 0.78 | KMT2A (0.50) | KMT2AMAPTL3MBTL1MEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3351538-A1 | TRIAZINE COMPOUNDS AND COMPOSITIONS THEREOF AND METHODS FOR TREATING MALARIA AND CHEMOPROPHYLAXIS | The United States of America, as represented by The Secretary of The Army, on behalf of Walter Reed Army Institute of Research (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-2970153-B1 | TRIAZINE COMPOUNDS AND COMPOSITIONS THEREOF AND METHODS FOR TREATING MALARIA AND CHEMOPROPHYLAXIS | THE US SECRETARY OF THE ARMY ON BEHALF OF WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9700562-B2 | Triazine compounds and compositions thereof and methods for treating malaria and chemoprophylaxis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF THE WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160213675-A1 | Triazine Compounds and Compositions Thereof and Methods for Treating Malaria and Chemoprophylaxis | WALTER REED ARMY INST OF RES THE USA AS REPRESENTED BY THE SEC OF THE ARMY ON BEHALF OF THE (US) | 2016-07-28 | — | — | US | disclosed |
| US-9334246-B2 | Substituted triazines for malaria treatment and chemoprophylaxis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF THE WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2016-05-10 | — | — | US | disclosed |
| EP-2970153-A1 | TRIAZINE COMPOUNDS AND COMPOSITIONS THEREOF AND METHODS FOR TREATING MALARIA AND CHEMOPROPHYLAXIS | The United States of America, as represented by The Secretary of The Army, on behalf of Walter Reed Army Institute of Research (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150210652-A1 | Substituted Triazines for Malaria Treatment and Chemoprophylaxis | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2015-07-30 | — | — | US | disclosed |
| WO-2014159993-A1 | TRIAZINE COMPOUNDS AND COMPOSITIONS THEREOF AND METHODS FOR TREATING MALARIA AND CHEMOPROPHYLAXIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF THE WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210652-A1 | Substituted Triazines for Malaria Treatment and Chemoprophylaxis | CYP3A5, HCCS, COX15 | KMT2A 490/4885MAPT 2297/4885TDP1 3930/4885 |
| US-20160213675-A1 | Triazine Compounds and Compositions Thereof and Methods for Treating Malaria and Chemoprophylaxis | HCCS, CYP3A5, COX15 | KMT2A 425/4885MAPT 1544/4885TDP1 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.